Stockscreener 앱 받기
2.04
0.00%
0.00
전일 마감가:
$2.04
열려 있는:
$2.05
하루 거래량:
130.09K
Relative Volume:
0.19
시가총액:
$65.07M
수익:
-
순이익/손실:
$-98.79M
주가수익비율:
-0.6239
EPS:
-3.27
순현금흐름:
$-51.66M
1주 성능:
-1.92%
1개월 성능:
+28.30%
6개월 성능:
+590.36%
1년 성능:
-38.37%
1일 변동 폭
$1.92
$2.08
1주일 범위
$1.92
$2.27
52주 변동 폭
$0.2404
$3.98
Relmada Therapeutics Inc Stock (RLMD) Company Profile
명칭
Relmada Therapeutics Inc
전화
646 876 3459
주소
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
RLMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
4.70 | 5.31B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.91 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.55 | 113.25M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2028 | 445.05M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.05 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-05 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-06-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-10-14 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2022-10-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 개시 | Mizuho | Buy |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-10-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-04 | 개시 | SunTrust | Buy |
| 2020-04-21 | 개시 | Goldman | Buy |
| 2020-01-27 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-12-16 | 개시 | Guggenheim | Buy |
모두보기
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Why Relmada Therapeutics Inc. stock is a value investor pickJuly 2025 Chart Watch & Free Technical Pattern Based Buy Signals - newser.com
Reversal indicators forming on Relmada Therapeutics Inc. stockEarnings Growth Report & High Accuracy Swing Trade Signals - newser.com
Will Relmada Therapeutics Inc. stock recover faster than marketPortfolio Risk Report & Free Long-Term Investment Growth Plans - newser.com
Combining machine learning predictions for Relmada Therapeutics Inc.Market Performance Recap & Stock Timing and Entry Methods - newser.com
Relmada seeking strategic options, stock climbs 5% - MSN
Relmada Therapeutics (NASDAQ:RLMD) Upgraded at Wall Street Zen - Defense World
D pipelineWeekly Trend Summary & High Return Trade Opportunity Guides - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Relmada Therapeutics (NASDAQ:RLMD) - MarketBeat
Relmada appoints Johns Hopkins professor to clinical advisory board - Investing.com
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 - Investing News Network
Relmada Therapeutics, Inc. Appoints Distinguished Urologic Oncologist, Max Kates, Md, to the Clinical Advisory Board - MarketScreener
Relmada appoints Johns Hopkins professor to clinical advisory board By Investing.com - Investing.com Australia
Relmada Therapeutics appoints Max Kates, MD, to the clinical advisory board to support development of NDV-01 - MarketScreener
Relmada Therapeutics Appoints Dr. Max Kates to Clinical Advisory Board to Support NDV-01 Phase 3 Program for Bladder Cancer - Quiver Quantitative
Phase 3 H1 2026 — Relmada Taps Max Kates to Guide NDV-01 for NMIBC, Bringing BRIDGE Trial Expertise - Stock Titan
Why Relmada Therapeutics Inc. stock is trending among retail tradersMarket Sentiment Summary & Verified Technical Trade Signals - newser.com
Using data tools to time your Relmada Therapeutics Inc. exit2025 Trading Recap & Weekly Watchlist for Hot Stocks - newser.com
Is Relmada Therapeutics Inc. (4E2) stock undervalued at current pricePortfolio Update Report & Low Drawdown Investment Strategies - newser.com
Earnings visualization tools for Relmada Therapeutics Inc.July 2025 Market Mood & Technical Pattern Recognition Alerts - newser.com
Relmada Therapeutics Inc. stock retracement – recovery analysis2025 Retail Activity & Precise Swing Trade Entry Alerts - newser.com
Using data filters to optimize entry into Relmada Therapeutics Inc.July 2025 Price Swings & Free Expert Approved Momentum Trade Ideas - newser.com
What drives Relmada Therapeutics Inc stock priceBlue Chip Stock Analysis & Investment Timing Techniques - earlytimes.in
Promising Penny Stocks To Watch In October 2025 - Yahoo Finance
Goldman Sachs Group Inc. Invests $33,000 in Relmada Therapeutics, Inc. $RLMD - Defense World
Using Python tools to backtest Relmada Therapeutics Inc. strategiesEarnings Beat & High Accuracy Swing Trade Signals - newser.com
Relmada Therapeutics Inc (RLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Relmada Therapeutics Inc 주식 (RLMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
| Kelly Paul Edward | Chief Operating Officer |
May 16 '25 |
Buy |
0.43 |
200,000 |
86,060 |
412,295 |
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
| Shenouda Maged | Chief Financial Officer |
May 20 '25 |
Buy |
0.52 |
60,000 |
31,422 |
288,335 |
| Shenouda Maged | Chief Financial Officer |
May 16 '25 |
Buy |
0.44 |
50,000 |
22,100 |
138,335 |
| Ence Chuck | CA and CO |
May 16 '25 |
Buy |
0.45 |
228,961 |
103,330 |
267,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 20 '25 |
Buy |
0.56 |
147,686 |
82,246 |
734,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 16 '25 |
Buy |
0.45 |
172,314 |
77,472 |
556,338 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 19 '25 |
Buy |
0.50 |
30,000 |
14,994 |
586,338 |
1.24%
자본화:
|
볼륨(24시간):